Industry joins with medical, patient groups to tackle rare diseases in Thailand
Biopharmaceutical company Takeda has signed a memorandum of understanding (MoU) with medical organisations and patient groups with the aim of improving the study, diagnosis and patient care of rare diseases.
Peter Streibl, the general manager of Takeda Thailand Co Ltd, a part of a leading biopharmaceutical company, participated in the joint signing ceremony for an MoU featuring a five-year framework to address rare diseases in Thailand.
The objective is for Thailand’s medical organisations, rare diseases patient foundations, and Takeda Thailand to develop a work plan and support activities that would improve the standard of care for patients with rare diseases in Thailand.
The work under the MoU consists of increasing the scope of studies and research work to better understand rare diseases, improving the skill and efficiency in diagnosis of rare diseases in Thailand, supporting educational programmes for healthcare professionals and patients, working with expert and patient advocacy groups to raise public awareness of rare diseases, supporting the development of a national database of rare diseases, and collaborating with key stakeholders for rare disease policy development.
Signatories came from Thailand’s medical organisations and patient foundations, including Medical Association of Thailand; Medical Genetics and Genomics Association (of Thailand); Medical Genetics Network, Genetics Society of Thailand; The Allergy, Asthma, and Immunology Association of Thailand; Thai Rare Disease Foundation; Genetic LSD Foundation and HAE Thailand.
